Age: 1.52
Sex: M
Vaccine: DTAP, HIBV, IPV
Symptoms: Disturbance in attention, Drug toxicity, Dyspnoea, Echolalia, Hearing impaired
Clinical narrative: It was reported that an 18 month old male pt received his fourth dose of Acthib and a third dose of IPOL on 1/10/02. 23 days later, the child developed signs of autism. The child's mother was concerned about the child's decreased vocabulary. Reportedly, the child only said "ma ma" and if he wanted something, he would go and get it, but he did not verbalize his needs. A developmental pediatric referral was given and the child was diagnosed with autism and "mercury in his body he cannot excrete." On 3/7/02, he had an audiology consult and mild hearing impairment was noted. In November 2002, at 28 months old, the child was seen by a developmental specialist. It was reported that he had delayed speech, sensory issues, distractibility, social impairment, communication impairment, repetitive and restrictive interests, preoccupation, finger posturing, "mild stereotypes," and repetitive motor movements. The child was diagnosed with autistic spectrum disorder and pervasive developmental disorder. A nurse reported that the "mercury he cannot excrete in his body" was a concern of the pt's mother. The mother has been asking about preservatives in vaccines and thought that this may be his problem. Lab tests were never done and the nurse did not think that they planned to do any testing. It was also noted that at three years of age, in approximately June 2003, the child had acute shortness of breath and cough after eating peanut butter. The pt was seen in the ER and given Benadryl and epinephrine and was discharged. He does have peanut allergy and now keeps epinephrine with him. The child's vaccination history includes a first dose of Recombivax-HB, 636274/0641K, administered on 6/6/00, a first dose of Infanrix, 961A2, a first dose of HibTiter, 470142, a first dose of IPOL, T0117, a second 0.5ml dose of Engerix B, 330A2, and a first dose of Prevnar, 471653, on 8/30/00. The child received his second dose of Infanrix, A975A2, a second dose of HibTiter, 473003, a second dose of IPOL, T0160, and a second dose of Prevnar, 471231, on 11/6/00. He also received his third 0.5ml dose of Infanrix, A970A2, a third dose of HibTiter, 474707, on 1/8/01. The child received his third dose of Recombivax HB, 638570/1700K, on 4/14/01. He received his first dose of varicella vaccine, 637972/1883K, and his fourth dose of prevnar, 479798, on 7/18/01 and his first dose of MMR II, 638599/0598K, on 10/9/01. Reportedly, the pt did not recover from these events. From additional information received on 14apr2004 from a health care professional, additional patient and vaccine information was provided. Patient name and address, county and person administering the vaccine were reported as well as where the patient was vaccinated and how the vaccine was purchased. The patient's birth weight and number of siblings was also provided. The lot number of the IPOL vaccination was corrected from 00Y26to OO426 and the onset date of the event was corrected from 02FEB2002 to 19FEB2002. Information regarding where the products were administered was also reported. Tripedia (lot number U0536D8) and ACTHIB (lot number U0151/UA637AA) were given together as TRIHIBIT in the left arm. The patient has not recovered from this event. No other information was provided. From additional information received on 14APR2004 from manufacturer  (WAES 0402USA00596), it was reported that this case was initially received from manufacturer and was assigned report number A0492211A. On 19FEB2002, speech delay was noted. No other information was provided. The patient did not recover from these events.